The successful completion of the Phase 3 trial and the achievement of all primary and secondary endpoints for Paltusotine in treating Acromegaly are critical milestones for Crinetics Pharmaceuticals. These results not only validate the efficacy of the drug but also pave the way for its commercialization, subject to FDA approval. The announcement of an expected NDA submission in the second half of 2024 further solidifies the company's timeline towards bringing the drug to market. Given these developments, investor confidence in CRNX is likely to increase, potentially leading to a positive impact on its stock price in the short term.